In a visionary move set to reshape the global healthcare landscape, the Department of Health – Abu Dhabi (DoH) has joined forces with Gilead Sciences, a global biopharmaceutical powerhouse, by signing dual Memoranda of Understanding (MoUs) during Abu Dhabi Global Healthcare Week 2025. This dynamic partnership isn’t just about paperwork—it’s about purpose. Together, they are gearing up to amplify clinical research, supercharge advanced therapies, and revolutionize healthcare innovation, solidifying Abu Dhabi’s status as a rising titan in global healthcare excellence.
This isn’t just another collaboration—it’s a calculated leap into the future. With a shared ambition to broaden medical accessibility and enhance treatment options, the DoH and Gilead are forging a pathway that places cutting-edge science at the heart of community well-being. From virology breakthroughs to cellular therapies, this partnership taps into frontier-level technologies that aim to tackle some of today’s most complex medical challenges.
In the presence of top-level leadership from both sides, this alliance signals more than just mutual commitment—it reflects a bold strategy to position Abu Dhabi as a global beacon for health and life sciences innovation. As the demand for smarter, more resilient healthcare systems grows, this move underscores the emirate’s dedication to proactive, patient-centric care—powered by research, backed by innovation, and built for the future.
With Gilead’s proven track record in pioneering treatments and Abu Dhabi’s unstoppable drive toward healthcare excellence, this collaboration is not just rewriting the rules—it’s rewriting the future of health. The message is clear: Abu Dhabi isn’t just keeping pace with the world—it’s setting the pace.
